Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseEmblemHealth Lyme IV Therapy Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentEmblemHealthPolicy MG.MM.ME.57d

    Lyme Disease Intravenous Treatment

    Customize your policy alerts

    Sign up for EmblemHealth Policy MG.MM.ME.57d alerts

    Get alerted when Policy MG.MM.ME.57d changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, acceptable agents, exclusions, and coding for IV antibiotic therapy for members with confirmed Lyme disease; applies to providers requesting preauthorization from EmblemHealth.

    Policy Summary
    PayerEmblemHealth
    PolicyLyme Disease Intravenous Treatment
    Policy CodePolicy MG.MM.ME.57d
    Change TypeAgent list additionthreshold clarified
    Effective DateMay 8, 2026
    Last ReviewMay 8, 2026
    Next Review DateMay 8, 2026
    Key ActionSubmit clinical documentation demonstrating the member meets the medical necessity criteria (including prior oral therapy and relevant labs/imaging) to obtain preauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    Doxycycline added as medically necessary for members intolerant to b-lactam antibiotics.

    Repeat or prolonged courses of IV antibiotics not considered medically necessary changed from >4 weeks to >8 weeks.

    2-4Initial IV duration (weeks)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >8w
    Repeat/prolonged not medically necessary
    Ceftriaxone, Cefotaxime, Pen G, Azithro/DoxyMedically necessary IV agents
    96365-96376, 99601-99602Procedure codes (infusion/home)

    Coverage Criteria for IV Antibiotic Therapy (Lyme Disease)

    Initial IV Therapy

    Covered when ANY of the following are met for members with confirmed Lyme disease

    Initial IV therapy indications: A. Lyme arthritis that persists after failing to respond to a 4-week course of appropriate oral antibiotic therapy; B. Lyme carditis with moderate to severe cardiac involvement as evidenced by any of the following: 1) 1st-degree heart block with PR interval ≥ 300 milliseconds; 2) myopericarditis; 3) 2nd- or higher degree atrio-ventricular block; C. Neurologic involvement (neuroborreliosis) evidenced by any of the following: 1) encephalomyelitis based on MRI imaging and CSF pleocytosis with no other cause found; 2) meningitis confirmed by CSF analysis showing a lymphocytic pleocytosis; 3) sensory/motor radiculoneuropathy or peripheral neuropathy (weakness and/or pain in the extremities or chest); D. All cases in pregnant women who exhibit Stage II (early dissemination with organ-specific manifestations) or Stage III (late disease with arthritis and/or neurologic complications).any

    From policy Section I

    Medically Necessary IV Antibiotics

    Medically necessary IV therapy agents include:

    Medically necessary IV agents: Ceftriaxone (Rocephin®); Cefotaxime (Claforan®); Penicillin G; Azithromycin (Zithromax®) or Doxycycline for members intolerant to b-lactam antibiotics.any

    From policy Section II

    Repeat Outpatient IV Therapy

    Repeat 2-4-week outpatient IV therapy is medically necessary when ALL of the following are met

    Repeat outpatient IV therapy criteria: A. The member has met the criteria for an initial course of intravenous antibiotic therapy with laboratory results obtained within the past 3 months; B. The member has completed an initial course of appropriate intravenous antibiotic therapy; C. The member has objective evidence of relapse of infection, progression of Lyme disease organ damage, and/or a new focus or type of organ damage.all

    From policy Limitations II

    Intravenous therapy with certain agent classes is not considered medically necessary for treatment of Lyme disease due to insufficient evidence of therapeutic value. Specifically, IV administration of carbapenems (e.g., doripenem, ertapenem, imipenem, meropenem), first‑generation cephalosporins (e.g., cefazolin), azole antifungals, and fluoroquinolones (e.g., levofloxacin, moxifloxacin) are excluded from coverage.

    Repeat or prolonged outpatient intravenous antibiotic courses beyond the policy threshold are not considered medically necessary. The policy specifies that repeat or prolonged courses of IV antibiotics >8 weeks have not been shown to improve net health outcomes and therefore are excluded from coverage.

    Procedure and Duration Coding

    Procedure Codes for IV/SubQ infusion and home infusionCPT
    96365Intravenous infusion; initial, up to 1 hour
    96366Intravenous infusion; each additional hour
    96369Subcutaneous infusion; initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
    96370Subcutaneous infusion; each additional hour
    96371Subcutaneous infusion; additional pump set-up with establishment of new subcutaneous infusion site(s)
    96374Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug
    96375Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of a new substance/drug
    96376Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of the same substance/drug (facility)
    99601Home infusion/specialty drug administration, per visit (up to 2 hours)
    99602Home infusion/specialty drug administration, each additional hour
    Initial IV therapy duration
    Standard initial IV antibiotic course length2-4 weeks
    Applies toMembers with confirmed Lyme disease meeting organ-specific criteria (e.g., refractory Lyme arthritis, moderate–severe carditis, neuroborreliosis, or eligible pregnant patients)
    Repeat course timing referenced elsewhereRepeat outpatient IV therapy, when allowed, is described as a 2-4-week course (see repeat therapy criteria)

    Provider Requirements and Authorization

    Prior Authorization

    Prior authorization required; include infusion/home-infusion codes

    Preauthorization is required for IV antibiotic therapy; submit clinical documentation that the member meets the policy medical necessity criteria. Applicable procedure codes for infusion and home infusion (listed in the policy) must be included with the authorization request: 96365, 96366, 96369, 96370, 96371, 96374, 96375, 96376, 99601, 99602.

    • Include the member's confirmed Lyme disease diagnosis and which Initial IV Therapy indication (A–D) is met.
    • Attach planned infusion procedure code(s) from the policy (CPT 96365–96376) or home infusion codes (99601–99602).
    Step Therapy

    Prior oral therapy and repeat IV therapy prerequisites

    For Lyme arthritis, IV therapy is eligible only after failure to respond to a 4‑week course of appropriate oral antibiotic therapy. Repeat outpatient IV therapy (2–4 week courses) is allowed only when the member previously completed an initial IV course and has objective evidence of relapse, progression, or a new focus of organ damage.

    Background

    Lyme disease may present as localized or disseminated infection affecting joints, heart, and the nervous system; IV antibiotics are reserved for specific organ‑involving manifestations or situations where oral therapy is inadequate. Indications that may justify IV therapy include refractory Lyme arthritis after an appropriate oral course, moderate‑to‑severe Lyme carditis (for example high‑degree AV block or myopericarditis), neuroborreliosis confirmed by compatible MRI and CSF findings or CSF lymphocytic pleocytosis, and cases in pregnancy with disseminated disease. The policy also clarifies that IV therapy is not appropriate for early localized disease (erythema migrans without systemic manifestations), flu‑like syndromes, initial treatment of Lyme arthritis, nonspecific chronic symptoms, prophylaxis of asymptomatic persons with only a positive immunologic test, or treatment strategies previously shown to lack benefit (including repeat/prolonged IV courses beyond 8 weeks and non‑antibiotic modalities listed in the exclusions).

    Definitions

    Lyme carditis — definition and thresholds
    Definition — moderate to severe Lyme carditisCardiac involvement evidenced by any of: 1) 1st-degree heart block with PR interval ≥ 300 milliseconds; 2) myopericarditis; 3) 2nd- or higher-degree atrio-ventricular (AV) block
    PR interval thresholdPR interval ≥ 300 milliseconds indicates clinically significant 1st-degree heart block
    Examples of advanced conduction diseaseMyopericarditis or 2nd-or-higher degree AV block qualify as moderate-to-severe involvement
    Neuroborreliosis (neurologic involvement) — definitions and diagnostic criteria
    Definition — neuroborreliosis (CNS/neurologic involvement)Neurologic involvement evidenced by any of: 1) encephalomyelitis based on MRI plus CSF pleocytosis with no other cause found; 2) meningitis confirmed by CSF lymphocytic pleocytosis; 3) sensory/motor radiculoneuropathy or peripheral neuropathy (weakness and/or pain)
    Policy Summary
    PayerEmblemHealth
    PolicyLyme Disease Intravenous Treatment
    Policy CodePolicy MG.MM.ME.57d
    Change TypeAgent list additionthreshold clarified
    Effective DateMay 8, 2026
    Last ReviewMay 8, 2026
    Next Review DateMay 8, 2026
    Key ActionSubmit clinical documentation demonstrating the member meets the medical necessity criteria (including prior oral therapy and relevant labs/imaging) to obtain preauthorization.
    SourceLink
    On This Page
    Coverage Criteria for IV Antibiotic Therapy (Lyme Disease)Procedure and Duration CodingProvider Requirements and AuthorizationBackgroundDefinitions
    • Document prior completion and lack of response to a 4‑week oral antibiotic course for Lyme arthritis.
    • For repeat IV therapy, document prior initial IV course completion and objective evidence (labs/imaging) within the timeframe required by the policy.
    Documentation Required

    Submit clinical evidence (prior therapy, labs, imaging) with request

    The treating physician or primary care provider must submit clinical evidence demonstrating the member meets the policy criteria (examples include documentation of prior oral therapy failure for arthritis, relevant laboratory or CSF results, and imaging findings). This documentation is required to obtain preauthorization.

    • Examples of clinical evidence: prior oral antibiotic course details, CSF analysis results, MRI findings, and lab results confirming Lyme disease.
    • For repeat outpatient IV therapy, provide lab results obtained within the past 3 months and documentation of the initial IV course.
    Denial Risk

    Missing documentation may lead to denial

    Failure to submit the required clinical evidence that the member meets the policy criteria may prevent preauthorization or payment and may result in denial on post‑payment review.

    • Missing documentation may include absence of prior oral therapy details, lack of CSF or imaging results, or no proof of completion of an initial IV course.
    • Ensure infusion procedure codes are included with the clinical documentation to support billing and authorization.
    CSF criteria for meningitis
    CSF analysis showing a lymphocytic pleocytosis confirms meningitis
    Encephalomyelitis diagnostic componentsRequires MRI imaging consistent with encephalomyelitis and CSF pleocytosis with no alternative cause identified